BioSpace News Archive

Novocure announced that Todd Longsworth, General Counsel, has resigned. Mr. Longsworth’s last day as General Counsel will be March 31.

DBV Technologies, a clinical-stage biopharmaceutical company, announced that the Company will host a conference call and live audio webcast on Thursday, March 3, 2022 at 5:00 p.m. ET to report full year 2021 financial results and provide a corporate update.

Select Medical Holdings Corporation announced results for its fourth quarter and year ended December 31, 2021 and the declaration of a cash dividend.

4WEB Medical, an orthopedic device company focused on developing innovative implants with an Advanced Structural Design utilizing its proprietary Truss Implant Technology™, announced the company’s launch of a comprehensive array of hyperlordotic lateral implants.

Apollo Medical Holdings, Inc. announced its consolidated financial results for the fourth quarter and year ended December 31, 2021.

Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic stem cell therapies, today announced that the preliminary data from a Phase 1b study of the Company’s JSP191 first-in-class anti-CD117 monoclonal antibody will be presented as a late breaking abstract at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings (TCT).

Tabula Rasa HealthCare, Inc., a leading healthcare technology company advancing the safe use of medications, reported financial results for the fourth quarter and full year ended December 31, 2021.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical study, “Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation” (OSPREY).

HitGen Inc. announced that the company has successfully completed a three-year drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation, a Japanese pharmaceutical company with the mission of “Creating hope for all facing illness”.

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three- and twelve-month periods ended December 31, 2021.